New Haven Drug Maker Starting Clinical Trial of Alzheimer's Treatment

A New Haven drugmaker and Hamden research center have been paired in a new, late-stage clinical trial to slow or stop the symptoms of Alzheimer’s disease.
Biohaven Pharmaceuticals announced it enrolled its first patient in August, and is still seeking more participants for the study, which is being coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego.
The GAP Center — the Geriatric and Adult Psychiatry Clinical Care and Research Center — in Hamden will be the first of 32 sites around the country to participate in the trial of Biohaven’s drug, troriluzole, which is designed to help people with mild to moderate Alzheimer’s.
The medication is based on another drug, riluzole, the first medication approved by the U.S. Food and Drug Administration to treat ALS more than 20 years ago.
A 2012 study found it extended ALS patients’ survival by two to three months.
Like riluzole, Biohaven’s troriluzole influences the brain chemicals that nerve cells use to communicate with each other. This helps protect against neurodegeneration — the loss or function of nerve cells.

Comments

  1. this is really nice to read..informative post is very good to read..thanks a lot!thank you for your interesting infomation. drug studies near me

    ReplyDelete

Post a Comment

Popular posts from this blog

There is mounting evidence that herpes leads to Alzheimers Disease

Alzheimers 2018

15 Things That Slow Down Alzheimer’s Disease